$DVAX
DYNAVAX TECHNOLOGIES CORP

2014 Q3 Form 10-Q Financial Statement

#000156459014005018 Filed on November 05, 2014

View on sec.gov

Income Statement

Concept 2014 Q3 2013 Q3
Revenue $2.209M $2.927M
YoY Change -24.53% 1.84%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.210M $6.730M
YoY Change -37.44% -5.48%
% of Gross Profit
Research & Development $28.07M $11.77M
YoY Change 138.5% -8.4%
% of Gross Profit
Depreciation & Amortization $340.0K $340.0K
YoY Change 0.0% 9.68%
% of Gross Profit
Operating Expenses $32.29M $11.77M
YoY Change 174.31% -8.4%
Operating Profit -$30.08M -$15.57M
YoY Change 93.2% -8.94%
Interest Expense $40.00K $24.00K
YoY Change 66.67% -95.93%
% of Operating Profit
Other Income/Expense, Net $216.0K -$120.0K
YoY Change -280.0% -38.78%
Pretax Income -$29.82M -$15.68M
YoY Change 90.18% -11.86%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$29.82M -$15.68M
YoY Change 90.23% -11.89%
Net Earnings / Revenue -1349.89% -535.53%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.134M -$856.8K
COMMON SHARES
Basic Shares Outstanding 183.0M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q3 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $130.6M $76.50M
YoY Change 70.72% -48.42%
Cash & Equivalents $19.70M $12.19M
Short-Term Investments $110.9M $64.30M
Other Short-Term Assets $3.600M $1.100M
YoY Change 227.27% -54.17%
Inventory
Prepaid Expenses
Receivables $700.0K $2.159M
Other Receivables $0.00 $0.00
Total Short-Term Assets $134.9M $79.75M
YoY Change 69.15% -48.34%
LONG-TERM ASSETS
Property, Plant & Equipment $8.100M $8.454M
YoY Change -4.19% 21.68%
Goodwill $2.532M
YoY Change 5.15%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.500M $302.0K
YoY Change 396.69% -31.05%
Total Long-Term Assets $12.00M $11.95M
YoY Change 0.46% 14.43%
TOTAL ASSETS
Total Short-Term Assets $134.9M $79.75M
Total Long-Term Assets $12.00M $11.95M
Total Assets $146.9M $91.70M
YoY Change 60.2% -44.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.000M $1.289M
YoY Change 287.9% -18.31%
Accrued Expenses $12.20M $8.148M
YoY Change 49.73% -11.08%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $22.80M $15.56M
YoY Change 46.5% -47.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.500M $988.0K
YoY Change 153.04% 58.33%
Total Long-Term Liabilities $2.500M $988.0K
YoY Change 153.04% 58.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.80M $15.56M
Total Long-Term Liabilities $2.500M $988.0K
Total Liabilities $25.30M $19.30M
YoY Change 31.07% -44.48%
SHAREHOLDERS EQUITY
Retained Earnings -$489.2M
YoY Change 17.88%
Common Stock $183.0K
YoY Change 2.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $121.6M $72.40M
YoY Change
Total Liabilities & Shareholders Equity $146.9M $91.70M
YoY Change 60.2% -44.37%

Cashflow Statement

Concept 2014 Q3 2013 Q3
OPERATING ACTIVITIES
Net Income -$29.82M -$15.68M
YoY Change 90.23% -11.89%
Depreciation, Depletion And Amortization $340.0K $340.0K
YoY Change 0.0% 9.68%
Cash From Operating Activities -$23.09M -$12.25M
YoY Change 88.49% -0.81%
INVESTING ACTIVITIES
Capital Expenditures -$290.0K -$490.0K
YoY Change -40.82% 48.48%
Acquisitions
YoY Change
Other Investing Activities $26.15M $7.150M
YoY Change 265.73% 303.95%
Cash From Investing Activities $25.87M $6.660M
YoY Change 288.44% 362.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 60.00K 70.00K
YoY Change -14.29% -92.47%
NET CHANGE
Cash From Operating Activities -23.09M -12.25M
Cash From Investing Activities 25.87M 6.660M
Cash From Financing Activities 60.00K 70.00K
Net Change In Cash 2.840M -5.520M
YoY Change -151.45% -44.69%
FREE CASH FLOW
Cash From Operating Activities -$23.09M -$12.25M
Capital Expenditures -$290.0K -$490.0K
Free Cash Flow -$22.80M -$11.76M
YoY Change 93.88% -2.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-53388000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-69394000
us-gaap Net Income Loss
NetIncomeLoss
-53664000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-23000
us-gaap Net Income Loss
NetIncomeLoss
-68436000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
69000
CY2014Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-921000
CY2014Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6000
CY2013Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
16000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1400000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1300000
CY2013Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
47000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-15675000
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
us-gaap Contracts Revenue
ContractsRevenue
3349000
us-gaap Revenue From Grants
RevenueFromGrants
2546000
us-gaap Revenue From Grants
RevenueFromGrants
3855000
us-gaap License And Services Revenue
LicenseAndServicesRevenue
10000
us-gaap License And Services Revenue
LicenseAndServicesRevenue
1200000
CY2013Q3 us-gaap Revenues
Revenues
2927000
us-gaap Revenues
Revenues
8755000
us-gaap Revenues
Revenues
8404000
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11770000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
64942000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38739000
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5807000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12325000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22243000
CY2013Q3 us-gaap Costs And Expenses
CostsAndExpenses
18495000
us-gaap Costs And Expenses
CostsAndExpenses
77653000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-30077000
us-gaap Operating Income Loss
OperatingIncomeLoss
-68898000
CY2014Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
42000
CY2013Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
37000
us-gaap Investment Income Interest
InvestmentIncomeInterest
162000
CY2013Q3 us-gaap Interest Expense
InterestExpense
24000
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
216000
CY2013Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-120000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
300000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-29819000
CY2013Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
600000
CY2013Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
600000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
4000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-692000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-224000
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12191000
dvax Supplemental Disposal Of Assets
SupplementalDisposalOfAssets
8000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28072000
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4083000
CY2014Q3 us-gaap Business Exit Costs1
BusinessExitCosts1
131000
CY2013Q3 us-gaap Business Exit Costs1
BusinessExitCosts1
918000
us-gaap Business Exit Costs1
BusinessExitCosts1
386000
us-gaap Business Exit Costs1
BusinessExitCosts1
918000
CY2014Q3 us-gaap Costs And Expenses
CostsAndExpenses
32286000
us-gaap Costs And Expenses
CostsAndExpenses
61900000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15568000
us-gaap Operating Income Loss
OperatingIncomeLoss
-53496000
us-gaap Investment Income Interest
InvestmentIncomeInterest
163000
us-gaap Interest Expense
InterestExpense
83000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-248000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.26
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
262908000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
182960000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
299000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
276000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
986000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-958000
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30741000
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15184000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1016000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-24000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-714000
us-gaap Share Based Compensation
ShareBasedCompensation
4532000
us-gaap Share Based Compensation
ShareBasedCompensation
10847000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-900000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1154000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
2203000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-932000
dvax Increase Decrease In Restricted Cash And Other Assets For Operating Activities
IncreaseDecreaseInRestrictedCashAndOtherAssetsForOperatingActivities
575000
dvax Increase Decrease In Restricted Cash And Other Assets For Operating Activities
IncreaseDecreaseInRestrictedCashAndOtherAssetsForOperatingActivities
-166000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3284000
CY2013Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
491000
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
183022000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
262883000
CY2014Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000
CY2013Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
18000
CY2013Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
473000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1027000
CY2014Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-922000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-877000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
4334000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-2489000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-799000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3191000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-56871000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-46830000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
44807000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
48573000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
99500000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
101105000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1207000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1316000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
53486000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
51216000
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
143000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
13000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
30000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
130000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
224000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
143000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
111000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
95000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3466000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4592000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7599000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19656000
dvax Supplemental Disposal Of Assets
SupplementalDisposalOfAssets
675000
CY2014Q3 us-gaap Deferred Rent Credit
DeferredRentCredit
600000
CY2014Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
400000
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
554000
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2236000
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2287000
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2336000
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1305000
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
2303000
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
11021000
us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
27700000
CY2013Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1000000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
31100000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2014Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
130600000
CY2013Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
189376000
CY2014Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
96598000
CY2014Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
14280000
CY2014Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
110878000
CY2014Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
96635000
CY2014Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
14281000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may differ materially from these estimates and assumptions.</p></div>
CY2014Q3 us-gaap Fair Value Equity Level1 To Level2 Transfers Amount
FairValueEquityLevel1ToLevel2TransfersAmount
0
CY2014Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
130534000
CY2013Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
189407000
CY2014Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
44000
CY2014Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
130572000
CY2014Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
110916000
CY2011 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
12000000
CY2014Q3 dvax Number Of Healthy Workers Placeebo Was Delivered By Inhalation
NumberOfHealthyWorkersPlaceeboWasDeliveredByInhalation
45
CY2014Q3 dvax Description Of Doses Well Tolerated
DescriptionOfDosesWellTolerated
15.4 mg/week
CY2014Q2 us-gaap Revenue From Grants
RevenueFromGrants
414000
CY2013Q2 us-gaap Revenue From Grants
RevenueFromGrants
1700000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
75000000
us-gaap Dilutive Securities
DilutiveSecurities
0
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
15765000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
5673000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
25000
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
18819000
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
18819000
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
10553000
CY2013Q4 dvax Share Based Compensation Arrangement By Share Based Payment Award Options And Equity Instruments Other Than Options Nonvested Weighted Average Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsNonvestedWeightedAveragePrice
3.17
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.68
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.54
CY2014Q3 dvax Share Based Compensation Arrangement By Share Based Payment Award Options And Equity Instruments Other Than Options Nonvested Weighted Average Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsNonvestedWeightedAveragePrice
2.77
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
2.77
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.34
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M21D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y1M21D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y10M17D
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
444000
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
444000
CY2014Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
421000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.52
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.43
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.018
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.011
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.014
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.014
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5100000
CY2014Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1586000
CY2013Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2845000
CY2014Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10900000
CY2014Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.50
CY2014Q3 dvax Number Of Warrants Exercised During Period
NumberOfWarrantsExercisedDuringPeriod
100
CY2013Q3 dvax Number Of Warrants Exercised During Period
NumberOfWarrantsExercisedDuringPeriod
84000
CY2014Q3 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
1000
us-gaap Convertible Preferred Stock Terms Of Conversion
ConvertiblePreferredStockTermsOfConversion
The holder is prohibited from converting the Series B Convertible Preferred Stock into shares of common stock if, as a result of such conversion, the holder and its affiliates would own more than 9.98% of the total number of shares of common stock then issued and outstanding.
us-gaap Convertible Preferred Stock Settlement Terms
ConvertiblePreferredStockSettlementTerms
In the event of the Company’s liquidation, dissolution, or winding up, holders of Series B Convertible Preferred Stock will receive a payment equal to $0.001 per share before any proceeds are distributed to the common stockholders.

Files In Submission

Name View Source Status
0001564590-14-005018-index-headers.html Edgar Link pending
0001564590-14-005018-index.html Edgar Link pending
0001564590-14-005018.txt Edgar Link pending
0001564590-14-005018-xbrl.zip Edgar Link pending
dvax-10q_20140930.htm Edgar Link pending
dvax-20140930.xml Edgar Link completed
dvax-20140930.xsd Edgar Link pending
dvax-20140930_cal.xml Edgar Link unprocessable
dvax-20140930_def.xml Edgar Link unprocessable
dvax-20140930_lab.xml Edgar Link unprocessable
dvax-20140930_pre.xml Edgar Link unprocessable
dvax-ex311_201409309.htm Edgar Link pending
dvax-ex312_201409308.htm Edgar Link pending
dvax-ex321_201409306.htm Edgar Link pending
dvax-ex322_201409307.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending